Host: |
Rabbit |
Applications: |
WB/ELISA |
Reactivity: |
Human |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Clonality: |
Polyclonal |
Conjugation: |
Unconjugated |
Isotype: |
IgG |
Formulation: |
PBS with 0.02% Sodium Azide, 50% Glycerol, pH 7.3. |
Purification: |
Affinity purification |
Concentration: |
Lot specific |
Dilution Range: |
WB:1:500-1:2000ELISA:Recommended starting concentration is 1 Mu g/mL. Please optimize the concentration based on your specific assay requirements. |
Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
Gene Symbol: |
ING1 |
Gene ID: |
3621 |
Uniprot ID: |
ING1_HUMAN |
Immunogen Region: |
80-180 aa |
Specificity: |
A synthetic peptide corresponding to a sequence within amino acids 80-180 of human ING1 (NP_937862.1). |
Immunogen Sequence: |
LRCGWFSSWPPPSKSAIPIG GGSRGAGRVSRWPPPHWLEA WRVSPLPLSPLSPATFGRGF IAVAVIPGLWARGRGCSSDR LPRPAGPARRQFQAASLLTR GWGRAWPWKQILKELDECYE RFSRETDGAQKRRMLHCVQR ALIRSQELGDEKIQIVSQMV ELVENRTRQVDSHVELFEAQ |
Tissue Specificity | Isoform 2 was expressed in all normal tissues and cells examined, as well as in all breast cancer and melanoma cell lines examined. Isoform 3 was expressed in testis, liver, and kidney, weakly expressed in colon and brain and not expressed in breast and cultured melanocytes. Isoform 4 was highly expressed in testis and weakly expressed in brain, but not expressed in breast, colon, kidney, melanocytes, breast cancer or melanoma cell lines. |
Function | Cooperates with p53/TP53 in the negative regulatory pathway of cell growth by modulating p53-dependent transcriptional activation. Implicated as a tumor suppressor gene. |
Protein Name | Inhibitor Of Growth Protein 1 |
Cellular Localisation | Nucleus |
Alternative Antibody Names | Anti-Inhibitor Of Growth Protein 1 antibodyAnti-ING1 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance